TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Haemocomplettan® P in Patients Experiencing Microvascular Bleeding While Undergoing Elective Complex Cardiac Surgery
Brief Summary: Fibrinogen concentrate is increasingly used in cardiac surgery to reverse coagulopathy. Whether its use reduces blood loss, transfusion and occurrence of clinical adverse events remains unknown.


Options:
A: Arm Label: Saline solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline solution | Arm Label: Fibrinogen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fibrinogen | Arm Label: Prothrombin complex; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prothrombin complex | Intervention Type: DRUG; Name: Fibrinogen; Assigned to Arm(s): Fibrinogen | Intervention Type: DRUG; Name: Saline solution; Assigned to Arm(s): Saline solution | Intervention Type: DRUG; Name: Prothrombin complex; Assigned to Arm(s): Prothrombin complex
B: Arm Label: Beriplex® P/N; Type: EXPERIMENTAL; Interventions: Biological: Beriplex® P/N (Kcentra) | Arm Label: Fresh frozen plasma; Type: ACTIVE_COMPARATOR; Interventions: Biological: Fresh frozen plasma | Intervention Type: BIOLOGICAL; Name: Beriplex® P/N (Kcentra); Assigned to Arm(s): Beriplex® P/N | Intervention Type: BIOLOGICAL; Name: Fresh frozen plasma; Assigned to Arm(s): Fresh frozen plasma
C: Arm Label: Albumin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Human albumin (Placebo) | Arm Label: Haemocomplettan® P; Type: EXPERIMENTAL; Interventions: Drug: Haemocomplettan® P | Intervention Type: DRUG; Name: Haemocomplettan® P; Assigned to Arm(s): Haemocomplettan® P | Intervention Type: DRUG; Name: Human albumin (Placebo); Assigned to Arm(s): Albumin
D: Arm Label: Freezed-dried plasma; Type: EXPERIMENTAL; Interventions: Drug: Freezed-dried plasma | Arm Label: Fresh-frozen plasma; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fresh-frozen plasma | Intervention Type: DRUG; Name: Freezed-dried plasma; Assigned to Arm(s): Freezed-dried plasma | Intervention Type: DRUG; Name: Fresh-frozen plasma; Assigned to Arm(s): Fresh-frozen plasma

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intervention to Reduce Dietary Sodium in Hemodialysis
Brief Summary: The purpose of this study is to test, in a randomized clinical trial of 200 hemodialysis patients, a behavioral intervention to reduce dietary sodium intake. The investigators will assess the impact on weight gain between dialysis treatments, blood pressures, symptoms, and health-related quality of life. The primary study hypotheses are that participants will gain less weight in between dialysis treatments, and that dietary recalls will demonstrate reduced consumption of dietary sodium.


Options:
A: Arm Label: SCT-based behavioral intervention; Type: EXPERIMENTAL; Interventions: Behavioral: SCT-based behavioral intervention | Arm Label: Attention control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention Control | Intervention Type: BEHAVIORAL; Name: SCT-based behavioral intervention; Assigned to Arm(s): SCT-based behavioral intervention | Intervention Type: BEHAVIORAL; Name: Attention Control; Assigned to Arm(s): Attention control
B: Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Website Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Website Intervention | Intervention Type: BEHAVIORAL; Name: Website Intervention; Assigned to Arm(s): Website Intervention
C: Arm Label: Full CARE+ Spanish computer-counseling group; Type: ACTIVE_COMPARATOR; Interventions: Other: CARE+ Spanish computer counseling session | Arm Label: Brief risk assessment study group only (control); Type: ACTIVE_COMPARATOR; Interventions: Other: CARE+ Spanish brief computer risk assessment session | Intervention Type: OTHER; Name: CARE+ Spanish computer counseling session; Assigned to Arm(s): Full CARE+ Spanish computer-counseling group | Intervention Type: OTHER; Name: CARE+ Spanish brief computer risk assessment session; Assigned to Arm(s): Brief risk assessment study group only (control)
D: Arm Label: Patient Navigation (PN); Type: EXPERIMENTAL; Interventions: Behavioral: Patient Navigation | Arm Label: Usual Care (UC); Type: OTHER; Interventions: Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Patient Navigation; Assigned to Arm(s): Patient Navigation (PN) | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care (UC)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intervention to Reduce Dietary Sodium in Hemodialysis
Brief Summary: The purpose of this study is to test, in a randomized clinical trial of 200 hemodialysis patients, a behavioral intervention to reduce dietary sodium intake. The investigators will assess the impact on weight gain between dialysis treatments, blood pressures, symptoms, and health-related quality of life. The primary study hypotheses are that participants will gain less weight in between dialysis treatments, and that dietary recalls will demonstrate reduced consumption of dietary sodium.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Behavioral Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Interventions for Dialysis Facilities | Intervention Type: BEHAVIORAL; Name: Behavioral Interventions for Dialysis Facilities; Assigned to Arm(s): Behavioral Intervention
B: Arm Label: SystemCHANGE; Type: EXPERIMENTAL; Interventions: Behavioral: SystemCHANGE | Arm Label: Patient-education attention-control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Patient-education attention control | Intervention Type: BEHAVIORAL; Name: SystemCHANGE; Assigned to Arm(s): SystemCHANGE | Intervention Type: BEHAVIORAL; Name: Patient-education attention control; Assigned to Arm(s): Patient-education attention-control
C: Arm Label: SCT-based behavioral intervention; Type: EXPERIMENTAL; Interventions: Behavioral: SCT-based behavioral intervention | Arm Label: Attention control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention Control | Intervention Type: BEHAVIORAL; Name: SCT-based behavioral intervention; Assigned to Arm(s): SCT-based behavioral intervention | Intervention Type: BEHAVIORAL; Name: Attention Control; Assigned to Arm(s): Attention control
D: Arm Label: Traditional Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: eNephro Application; Type: EXPERIMENTAL; Interventions: Device: Telemedicine System | Intervention Type: DEVICE; Name: Telemedicine System; Assigned to Arm(s): eNephro Application

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intervention to Reduce Dietary Sodium in Hemodialysis
Brief Summary: The purpose of this study is to test, in a randomized clinical trial of 200 hemodialysis patients, a behavioral intervention to reduce dietary sodium intake. The investigators will assess the impact on weight gain between dialysis treatments, blood pressures, symptoms, and health-related quality of life. The primary study hypotheses are that participants will gain less weight in between dialysis treatments, and that dietary recalls will demonstrate reduced consumption of dietary sodium.


Options:
A: Arm Label: SCT-based behavioral intervention; Type: EXPERIMENTAL; Interventions: Behavioral: SCT-based behavioral intervention | Arm Label: Attention control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention Control | Intervention Type: BEHAVIORAL; Name: SCT-based behavioral intervention; Assigned to Arm(s): SCT-based behavioral intervention | Intervention Type: BEHAVIORAL; Name: Attention Control; Assigned to Arm(s): Attention control
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Dietary sodium reduction; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary sodium reduction | Intervention Type: BEHAVIORAL; Name: Dietary sodium reduction; Assigned to Arm(s): Dietary sodium reduction
C: Arm Label: Low Sodium Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Low Sodium Diet | Arm Label: Usual Diet; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Low Sodium Diet; Assigned to Arm(s): Low Sodium Diet
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: OxSalt care bundle | Arm Label: Normal care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: OxSalt care bundle; Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intervention to Reduce Dietary Sodium in Hemodialysis
Brief Summary: The purpose of this study is to test, in a randomized clinical trial of 200 hemodialysis patients, a behavioral intervention to reduce dietary sodium intake. The investigators will assess the impact on weight gain between dialysis treatments, blood pressures, symptoms, and health-related quality of life. The primary study hypotheses are that participants will gain less weight in between dialysis treatments, and that dietary recalls will demonstrate reduced consumption of dietary sodium.


Options:
A: Arm Label: Integrated Chronic Kidney Disease care; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated Chronic Kidney Disease care | Arm Label: Conventional CKD care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Conventional CKD care | Intervention Type: BEHAVIORAL; Name: Integrated Chronic Kidney Disease care; Assigned to Arm(s): Integrated Chronic Kidney Disease care | Intervention Type: BEHAVIORAL; Name: Conventional CKD care; Assigned to Arm(s): Conventional CKD care
B: Arm Label: Group Based; Type: EXPERIMENTAL; Interventions: Behavioral: Group-Based (GB) Intervention | Arm Label: Home-Based; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Home-Based (HB) Intervention | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Group-Based (GB) Intervention; Assigned to Arm(s): Group Based | Intervention Type: BEHAVIORAL; Name: Home-Based (HB) Intervention; Assigned to Arm(s): Home-Based
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: dietary education | Intervention Type: BEHAVIORAL; Name: dietary education; Assigned to Arm(s): A
D: Arm Label: SCT-based behavioral intervention; Type: EXPERIMENTAL; Interventions: Behavioral: SCT-based behavioral intervention | Arm Label: Attention control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention Control | Intervention Type: BEHAVIORAL; Name: SCT-based behavioral intervention; Assigned to Arm(s): SCT-based behavioral intervention | Intervention Type: BEHAVIORAL; Name: Attention Control; Assigned to Arm(s): Attention control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intervention to Reduce Dietary Sodium in Hemodialysis
Brief Summary: The purpose of this study is to test, in a randomized clinical trial of 200 hemodialysis patients, a behavioral intervention to reduce dietary sodium intake. The investigators will assess the impact on weight gain between dialysis treatments, blood pressures, symptoms, and health-related quality of life. The primary study hypotheses are that participants will gain less weight in between dialysis treatments, and that dietary recalls will demonstrate reduced consumption of dietary sodium.


Options:
A: Arm Label: Intervention SUBLIME; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention SUBLIME | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intervention SUBLIME; Assigned to Arm(s): Intervention SUBLIME
B: Arm Label: Study group; Type: EXPERIMENTAL; Interventions: Behavioral: Low-salt educational programme, Behavioral: Low-salt Bangladeshi educational programme | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Low-salt educational programme; Assigned to Arm(s): Study group | Intervention Type: BEHAVIORAL; Name: Low-salt Bangladeshi educational programme; Assigned to Arm(s): Study group | Intervention Type: BEHAVIORAL; Name: Low-salt Bangladeshi educational programme; Assigned to Arm(s): Study group
C: Arm Label: Diuretic treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amiloride, Drug: Hydrochlorothiazide | Arm Label: Low-sodium diet; Type: ACTIVE_COMPARATOR; Interventions: Other: Low-sodium diet | Intervention Type: DRUG; Name: Amiloride; Assigned to Arm(s): Diuretic treatment | Intervention Type: DRUG; Name: Hydrochlorothiazide; Assigned to Arm(s): Diuretic treatment | Intervention Type: OTHER; Name: Low-sodium diet; Assigned to Arm(s): Low-sodium diet
D: Arm Label: SCT-based behavioral intervention; Type: EXPERIMENTAL; Interventions: Behavioral: SCT-based behavioral intervention | Arm Label: Attention control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention Control | Intervention Type: BEHAVIORAL; Name: SCT-based behavioral intervention; Assigned to Arm(s): SCT-based behavioral intervention | Intervention Type: BEHAVIORAL; Name: Attention Control; Assigned to Arm(s): Attention control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 in Patients With DSM-IV-TR Schizophrenia
Brief Summary: This study is designed to compare 3 doses of LY2140023 for the treatment of schizophrenia as assessed at endpoint (up to 7 weeks) using the Clinical Utility Index (CUI), a measure of efficacy, safety, and tolerability.


Options:
A: Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A
B: Arm Label: LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: Olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: olanzapine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): LY2140023 | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): Olanzapine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cariprazine 1.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Cariprazine 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Cariprazine 4.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Risperidone 4.0 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Cariprazine; Assigned to Arm(s): Cariprazine 1.5 mg, Cariprazine 3.0 mg, Cariprazine 4.5 mg | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Risperidone 4.0 mg
D: Arm Label: 10 milligrams (mg) LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 80 mg LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 160 mg LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 10 milligrams (mg) LY2140023, 160 mg LY2140023, 80 mg LY2140023 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 in Patients With DSM-IV-TR Schizophrenia
Brief Summary: This study is designed to compare 3 doses of LY2140023 for the treatment of schizophrenia as assessed at endpoint (up to 7 weeks) using the Clinical Utility Index (CUI), a measure of efficacy, safety, and tolerability.


Options:
A: Arm Label: 80 milligrams (mg) LY2140023, BID; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 40 mg LY2140023, BID; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 10 mg LY2140023, BID; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 10 mg LY2140023, BID, 40 mg LY2140023, BID, 80 milligrams (mg) LY2140023, BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: paliperidone palmitate; Assigned to Arm(s): N/A
C: Arm Label: 10 milligrams (mg) LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 80 mg LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 160 mg LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 10 milligrams (mg) LY2140023, 160 mg LY2140023, 80 mg LY2140023 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: MK-0777 8 mg; Type: EXPERIMENTAL; Interventions: Drug: MK-0777 | Arm Label: MK-0777 3 mg; Type: EXPERIMENTAL; Interventions: Drug: MK-0777 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: MK-0777; Assigned to Arm(s): MK-0777 8 mg | Intervention Type: DRUG; Name: MK-0777; Assigned to Arm(s): MK-0777 3 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Diabetes Control Through Peer Counseling and Incentives
Brief Summary: The specific aims of this study are to test whether in a cohort of low-income minority veterans with poor diabetes mellitus (DM) control:

1. Peer counseling is an effective means of reducing HbA1c (a measure of glucose control).
2. Financial incentives are an effective means of reducing HbA1c. This is a randomized controlled pilot study. There will be 3 arms: 1) a control group of poorly controlled diabetics getting usual care; 2) peer counseling with no incentives; and 3) financial incentives without peers. Ultimately, contingent on the success of this intervention, the researchers plan to apply for funding for a large scale intervention employing both peer counseling and incentives to improve DM control in low income and minority patients who are at high risk for premature morbidity and mortality.


Options:
A: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Technology Assisted Case Management; Type: EXPERIMENTAL; Interventions: Behavioral: Technology-Assisted Case Management | Intervention Type: BEHAVIORAL; Name: Technology-Assisted Case Management; Assigned to Arm(s): Technology Assisted Case Management
B: Arm Label: dashboard team care intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes Dashboard Intervention | Arm Label: usual diabetes team control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Diabetes Care | Intervention Type: BEHAVIORAL; Name: Diabetes Dashboard Intervention; Assigned to Arm(s): dashboard team care intervention | Intervention Type: BEHAVIORAL; Name: Usual Diabetes Care; Assigned to Arm(s): usual diabetes team control
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Peer counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Assigned a peer counselor | Arm Label: Financial incentives; Type: EXPERIMENTAL; Interventions: Behavioral: Financial incentives | Intervention Type: BEHAVIORAL; Name: Assigned a peer counselor; Assigned to Arm(s): Peer counseling | Intervention Type: BEHAVIORAL; Name: Financial incentives; Assigned to Arm(s): Financial incentives
D: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Diabetes Peer Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes Peer Counseling | Intervention Type: BEHAVIORAL; Name: Diabetes Peer Counseling; Assigned to Arm(s): Diabetes Peer Counseling

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Phase-III-trial of Simultaneous Radiochemotherapy (RCT) of Locally Advanced Head and Neck Cancer in the Stages III and IV A-B: Comparing Dose Reduced Radiotherapy (63,6 Gy) With Paclitaxel/Cisplatin to Standard Radiotherapy (70,2 Gy) With 5-Fluorouracil/Cisplatin
Brief Summary: Reduced RT with Pac/Cis vs. standard RCT with 5-FU/Cis


Options:
A: Arm Label: ARM A; Type: EXPERIMENTAL; Interventions: Drug: docetaxel - cisplatin - 5-fluorouracil, Radiation: radiotherapy, Drug: cetuximab | Arm Label: ARM B; Type: ACTIVE_COMPARATOR; Interventions: Drug: cisplatin, Radiation: radiotherapy | Intervention Type: DRUG; Name: docetaxel - cisplatin - 5-fluorouracil; Assigned to Arm(s): ARM A | Intervention Type: RADIATION; Name: radiotherapy; Assigned to Arm(s): ARM A | Intervention Type: DRUG; Name: cetuximab; Assigned to Arm(s): ARM A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): ARM B | Intervention Type: RADIATION; Name: radiotherapy; Assigned to Arm(s): ARM B
B: Arm Label: Reduced RT + Pacitaxel/Cisplatin; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel/Cisplatin, Radiation: Reduced RT | Arm Label: Standard RT + 5-Fluorouracil/Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-FU/Cisplatin, Radiation: Standard RT | Intervention Type: DRUG; Name: Paclitaxel/Cisplatin; Assigned to Arm(s): Reduced RT + Pacitaxel/Cisplatin | Intervention Type: RADIATION; Name: Reduced RT; Assigned to Arm(s): Reduced RT + Pacitaxel/Cisplatin | Intervention Type: DRUG; Name: 5-FU/Cisplatin; Assigned to Arm(s): Standard RT + 5-Fluorouracil/Cisplatin | Intervention Type: RADIATION; Name: Standard RT; Assigned to Arm(s): Standard RT + 5-Fluorouracil/Cisplatin
C: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: carboplatin, Drug: cisplatin, Drug: docetaxel, Drug: fluorouracil | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: cisplatin | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): Arm I | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): Arm I | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): Arm I
D: Arm Label: Arm I; Type: PLACEBO_COMPARATOR; Interventions: Procedure: conventional surgery, Radiation: radiation therapy | Arm Label: Arm II; Type: ACTIVE_COMPARATOR; Interventions: Biological: cetuximab, Procedure: conventional surgery, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): Arm II | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Arm I, Arm II | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm I, Arm II

Answer: B